EP4630395A1 - Processes for making endochin-like quinolones from alkyl 3-(3- alkoxyphenyl)amino)-2-(4-(4-alkoxy)phenoxy)phenyl)but-2-enoate - Google Patents

Processes for making endochin-like quinolones from alkyl 3-(3- alkoxyphenyl)amino)-2-(4-(4-alkoxy)phenoxy)phenyl)but-2-enoate

Info

Publication number
EP4630395A1
EP4630395A1 EP23817776.0A EP23817776A EP4630395A1 EP 4630395 A1 EP4630395 A1 EP 4630395A1 EP 23817776 A EP23817776 A EP 23817776A EP 4630395 A1 EP4630395 A1 EP 4630395A1
Authority
EP
European Patent Office
Prior art keywords
compound
formula
alkyl
mmol
phenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23817776.0A
Other languages
German (de)
French (fr)
Inventor
Stephan Veit
Christophe Pierre Alain Chassaing
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intervet International BV
Original Assignee
Intervet International BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet International BV filed Critical Intervet International BV
Publication of EP4630395A1 publication Critical patent/EP4630395A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C07C69/736—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/64—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by introduction of functional groups containing oxygen only in singly bound form

Definitions

  • U.S. Patent No. 8,598,354 discloses endochin-like quinolone compounds having antiparasitic or anti-infectious activity including 6-fluoro-7-methoxy-2-methyl-3-(4- (4- (trifluoromethoxy)phenoxy)phenyl)quinolin-4(lH)-one (ELQ-316) (See Figure 4, sheet 23).
  • McConnell et al discloses additional endochin-like quinolone compounds including 7-methoxy-2-methyl-3-(4-(4 (trifluoromethoxy)phenoxy)phenyl) quinolin-4(lH)-one (see Table 1, compound 7 B).
  • WO/2021/231335 discloses synthetic methods and novel intermediates in the preparation of 3- aryl endochin-like quinolone (ELQ) compounds including ELQ-316 that are amenable to industrial scaleup production.
  • ELQ 3- aryl endochin-like quinolone
  • Pou, et al. disclose synthetic routes to endochin-like quinolone compounds such as ELQ-300, ELQ-316, and other antiparasitic quinolones (Org. Process Res. Dev. 2021, 25, 1841-1852). Specifically, Pou discloses another process for making a compound similar to compound 4 which involves the use of a metal (copper) at elevated temperature 160 °C. However, the reported yields remain moderate, 60% - 70%. Furthermore, Pou describes the use of acetic anhydride for introducing an acetyl group on compound 4 which leads to a mixture of compounds 5 and 5a. This mixture needs to be treated with an acid (para toluenesulfonic acid, TsOH) to convert 5a back to 5. This is an additional step and it is not easy to remove the TsOH from the product which had to be carried over in the next step.
  • TsOH para toluenesulfonic acid
  • Vaswani et al. (Org. Lett. 2014, 16, 4114-4117) discloses the use of lithium bis(trimethylsilyl)amide (LiHMDS) and l-(lH-imidazol-l-yl)ethanone at low temperature to acylate aryl a-methyl esters.
  • LiHMDS lithium bis(trimethylsilyl)amide
  • l-(lH-imidazol-l-yl)ethanone at low temperature to acylate aryl a-methyl esters.
  • WO2021231335 discloses novel intermediates useful in the synthesis of endochin-like quinolone compounds. Summary of the Invention
  • An embodiment of the invention is a process for preparing a compound of Formula 4 wherein Ri is C1-C2 alkyl, preferably Ci alkyl, comprising reacting a compound of Formula 3 with phenyliodonium diacetate (PhI(OAc)2) and an orthoformate to yield the compound of
  • R2 is C1-C2 alkyl, preferably Ci alkyl, wherein R is H, Cl or F, and Ri is C1-C2 alkyl which avoids the use of any metal catalysis (e.g. copper) and of harsh reaction conditions and allows the final compound to be isolated in very high purity (>99%) and in the absence of any trace of residual metal.
  • Scheme 1 is representative where R is F and R2 is methyl.
  • AcONa is sodium acetate.
  • DMF is A,A-dimethyl formamide.
  • DMSO dimethylsulfoxide
  • LiHMDS is lithium bis(trimethylsilyl)amide or lithium hexamethyldisilazane.
  • LIMP is lithium tetramethylpiperidide.
  • LDA is lithium diisopropylamide.
  • MeOH is methanol
  • NMP is A-methyl-2-pyrrolidone.
  • PCh is phosphorus trichloride.
  • PCh is phosphorous pentachloride.
  • PhI(OAc)2 is (diacetoxyiodo)benzene or phenyliodonium diacetate.
  • POCI3 is phosphorus oxychloride.
  • THF is tetrahydrofuran.
  • TMOF is trimethyl orthoformate.
  • Residual metals in pharmaceuticals that have no therapeutic value are considered contaminants and their levels are strictly controlled by the various regulatory agencies around the world (ICH guideline Q3D (R2) on elemental impurities).
  • Substantially free means not present in numbers or quantities in excess of those that can be expected to result from and be consistent with normal handling and good cultural practices employed in the production and marketing of the commodity.
  • residual metal for example copper, in an active pharmaceutical ingredient (api) given parenterally, it means less than 300 ppm of the residual metal in the api composition.
  • reaction is conducted in an alcohol.
  • 150°C between about 130°C to about 150°C, between about 100°C to about 145°C, between about 125°C to about 145°C, between about 100°C to about 140°C, preferably about 135°C to about 145°C.
  • the temperature is about 140°C.
  • the reaction further comprises a base.
  • the base is potassium carbonate, sodium carbonate or cesium carbonate, preferably potassium carbonate.
  • the base is sodium carbonate.
  • the base is cesium carbonate.
  • the reaction further comprises a solvent.
  • the solvent is /V,/V-di methyl formamide (DMF), N- methyl-2-pyrrolidone (NMP) or dimethylsulfoxide (DMSO), preferably DMF.
  • the solvent is NMP.
  • the solvent is DMSO.
  • the process further comprises reacting the compound of Formula 4 to produce the compound of Formula (I) wherein R is H, Cl or F, preferably F and R2 is C1-C2 alkyl, preferably Ci alkyl.
  • R is Cl and R2 is Ci alkyl.
  • R is F and R2 is Ci alkyl.
  • R is H and R2 is Ci alkyl.
  • the compound of Formula (I) is substantially free of residual metal.
  • Another embodiment of the invention is a compound of Formula 4
  • An embodiment of the invention is a process for preparing a compound of Formula 5 wherein Ri is C1-C2 alkyl, preferably Ci alkyl, comprising reacting a compound of Formula 4 with a base and then an alkylating agent to produce the compound of Formula 5.
  • the base is lithium bis(trimethylsilyl)amide (LiHMDS), lithium tetramethylpiperidide (LTMP) or lithium diisopropylamide (LDA), preferably LiHMDS.
  • the base is LTMP.
  • the alkylating agent is acetylimidazole.
  • the process is quenched at a temperature less than about 0°C to about 20°C, preferably less than about 10°C. In another embodiment of the invention, the process is quenched at a temperature of between about 0°C to about 20°C, or between about 0°C to about 10°C or between about 10°C to about 20°C.
  • the process further comprises reacting the compound of Formula 5 to produce the compound of Formula (I) wherein R is H, Cl or F, preferably F and R2 is C1-C2 alkyl, preferably Ci alkyl.
  • R is Cl and R2 is Ci alkyl.
  • R is F and R2 is Ci alkyl.
  • R is H and R2 is Ci alkyl.
  • Another embodiment of the invention is a compound of Formula 5
  • An embodiment of the invention is a process for preparing a compound of Formula 7 wherein R is H, Cl or F, preferably F and Ri is C1-C2 alkyl, preferably Ci alkyl, comprising reacting a compound of Formula 5 with a compound of Formula 6 wherein R is H, Cl or F, preferably F and R2 is C1-C2 alkyl, preferably Ci alkyl. yield the compound of Formula 7.
  • a solvent is used in the process.
  • the solvent is an aprotic apolar solvent such as cyclohexane, toluene, heptane, xylene, or mixtures thereof, preferably cyclohexane.
  • the solvent is heptane.
  • the solvent is toluene.
  • the temperature of the process is between about 50 °C and about 140 °C, between about 60 °C and about 130 °C, about 70 °C and about 120 °C, about 80 °C and about 120 °C, about 85 °C and about 110 °C, preferably about 90 °C and about 110 °C.
  • the temperature is about 110°C.
  • the process further comprises reacting the compound of Formula 7 with phosphorus oxychloride (POCh), phosphorus trichloride (PCI3), or phosphorous pentachloride (PCI5), preferably POCI3, to yield a compound of Formula 8 wherein R is H, Cl or F, preferably F and R2 is C1-C2 alkyl, preferably Ci alkyl.
  • POCh phosphorus oxychloride
  • PCI3 phosphorus trichloride
  • PCI5 phosphorous pentachloride
  • the temperature of the process is between about 50 °C and about 140 °C, between about 60 °C and about 130 °C, about 70 °C and about 120 °C, about 80 °C and about 120 °C, about 85 °C and about 110 °C, preferably about 90 °C and about 110 °C.
  • the temperature is about 100°C.
  • the process further comprises reacting the compound of Formula 8 to produce the compound of Formula (I) wherein R is H, Cl or F, preferably F and R2 is C1-C2 alkyl, preferably Ci alkyl.
  • R is Cl and R2 is Ci alkyl.
  • R is F and R2 is Ci alkyl. In another embodiment of the invention, R is H and R2 is Ci alkyl.
  • the process to form the compound of Formula (I) from the compound of Formula 8 is carried out in situ from the process to form the compound of Formula 8 from the compound of Formula 7.
  • Another embodiment of the invention is a compound of Formula 7
  • An embodiment of the invention is a process for preparing a compound of Formula (I) comprising reacting a compound of Formula 8 with an acetate salt in an acid to yield the compound of Formula (I), wherein R is H, Cl or F, preferably F and R2 is C1-C2 alkyl, preferably Ci alkyl.
  • R is Cl and R2 is Ci alkyl. In another embodiment of the invention, R is F and R2 is Ci alkyl.
  • the acetate salt is potassium acetate or sodium acetate, preferably sodium acetate.
  • the acetate salt is potassium acetate.
  • the acid is acetic acid or a C1-C4 aliphatic acid, preferably acetic acid.
  • the acid is a C1-C4 aliphatic acid.
  • the process to form the compound of Formula (I) from the compound of Formula 8 is carried out in situ from a process to form the compound of Formula 8 from the compound of Formula 7
  • An alternative embodiment of the invention is a to produce the compound of Formula (I) wherein R is H, Cl or F, preferably F and R2 is C1-C2 alkyl, preferably Ci alkyl, comprising i) reacting a compound of Formula 1 with a compound of Formula 2 to yield the compound of Formula 3, wherein the temperature of the reaction is between about 100°C to about 170°C; ii) reacting a compound of Formula 3 with phenyliodonium diacetate (PhI(OAc)2) and an orthoformate to produce the compound of Formula 4 iii) reacting a compound of Formula 4 with a base and then an alkylating agent to produce the compound of Formula 5 iv) reacting the compound of Formula 5 with a compound of formula 6 to produce the compound of Formula (I).
  • R is H, Cl or F, preferably F and R2 is C1-C2 alkyl, preferably Ci alkyl
  • An alternative embodiment of the invention is a to produce the compound of Formula (I) wherein R is H, Cl or F, preferably F and R2 is C1-C2 alkyl, preferably Ci alkyl, comprising i) reacting a compound of Formula 1 with a compound of Formula 2 to yield the compound of Formula 3, wherein the temperature of the reaction is between about 100°C to about 170°C; ii) reacting a compound of Formula 3 with phenyliodonium diacetate (PhI(OAc)2) and an orthoformate to produce the compound of Formula 4 iii) reacting a compound of Formula 4 with a base and then an alkylating agent to produce the compound of Formula 5 iv) reacting the compound of Formula 5 with a compound of Formula 6 wherein R is H, Cl or F, preferably F and R2 is C1-C2 alkyl, preferably Ci alkyl.
  • R is H, Cl or F, preferably F and R2 is C1-C2 alkyl, preferably
  • An alternative embodiment of the invention is a to produce the compound of Formula (I) wherein R is H, Cl or F, preferably F and R2 is C1-C2 alkyl, preferably Ci alkyl, comprising i) reacting a compound of Formula 1 with a compound of Formula 2 to yield the compound of Formula 3, wherein the temperature of the reaction is between about 100°C to about 170°C; ii) reacting a compound of Formula 3 with phenyliodonium diacetate (PhI(OAc)2) and an orthoformate to produce the compound of Formula 4 iii) reacting a compound of Formula 4 with a base and then an alkylating agent to produce the compound of Formula 5 iv) reacting the compound of Formula 5 with a compound of Formula 6 wherein R is H, Cl or F, preferably F and R2 is C1-C2 alkyl, preferably Ci alkyl.
  • R is H, Cl or F, preferably F and R2 is C1-C2 alkyl, preferably
  • intermediate compounds 3, 4, 5 and 7 are carried on to the subsequent reaction step in concentrated solutions without complete drying.
  • the intermediate compound 3 is carried on to the subsequent reaction step in a concentrated solution without complete drying.
  • the intermediate compound 4 is carried on to the subsequent reaction step in a concentrated solution without complete drying.
  • the intermediate compound 5 is carried on to the subsequent reaction step in a concentrated solution without complete drying.
  • the intermediate compound 7 is carried on to the subsequent reaction step in a concentrated solution without complete drying.
  • Agilent Technologies UHPLC/MSD 6130 B Series 1290 composed of binary pump G7120A included degasser, Well plate sampler G4226A, Column oven G1316B, Diode array detector G4212A, Mass detector G6130B Quadrupole LC/MS with ESLsource.
  • Eluents A: acetonitrile with 0.05 % (vol./vol.) formic acid.
  • ESI/MS positive and negative ions scan: 100-1000 m/z;
  • Step 1 Preparation of l-(4-(4-(trifhioromethoxy)phenoxy) phenyl)ethan-l-one (Compound 3)
  • Step 2 Preparation of methyl 2-(4-(4-(trifluoromethoxy)phenoxy)phenyl)acetate (Compound 4)
  • step 1 The crude product obtained from step 1 (43.6 g, 140 mmol) was dissolved in methanol (430 mL), trimethoxymethane (127 mL, 1161 mmol) was added and the temperature of the resulting mixture was adjusted to 10 °C. Concentrated sulfuric acid (64.8 mL, 1161 mL) and phenyliodine(III) diacetate (50.1 g, 152 mmol) were sequentially added while holding the temperature of the reaction mixture between 10 to 16 °C. After completion of the additions, the reaction mixture was allowed to reach room temperature and was stirred for 90 min. The temperature was then adjusted to 5 °C and water (500 mL) was added.
  • the volume of the resulting mixture was reduced under reduced pressure (distillated volume ⁇ 70 mL), water (I L) was added and the pH was set to 7 by the addition of sodium hydrogen carbonate.
  • the aqueous solution was extracted with dichloromethane (2 x 300 mL) and the combined organic layers were dried and concentrated under reduced pressure to afford the desired product (71.3 g, 63 wt.%) in the presence of iodobenzene (37 wt.%).
  • Step 1 Preparation of methyl 3-oxo-2-(4-(4-(trifluoromethoxy)phenoxy)phenyl) butanoate (Compound 5)
  • Methyl 2-(4-(4-(trifluoromethoxy)phenoxy)phenyl)acetate (20.0 g, 63 wt.%, 38.6 mmol) obtained from step 2 of example 1 and l-(177-imidazol-l-yl)ethan-l-one (5.1 g, 46.3 mmol) were placed under nitrogen atmosphere and were dissolved in a mixture of dry tetrahydrofuran (200 mL) and dry 7V,7V-di methylacetamide (20 mL).
  • the temperature of the resulting solution was set to - 30 °C and a IM solution of lithium bis(trimethylsilyl)amide in tetrahydrofuran (93 mL, 93 mmol) was added while maintaining the temperature between -31 to -28 °C. After completion of the addition (about 20 min), the resulting mixture was stirred for 1 h between -30 to -25 °C. Cooling was stopped and saturated aqueous ammonium chloride (100 mL) was slowly added to the reaction mixture which resulted in an increase in temperature to -1 °C. The mixture was allowed to reach room temperature and was stirred for 30 min.
  • Step 2 Preparation of methyl 3-((4-fluoro-3-methoxyphenyl)amino)-2-(4-(4-
  • step 1 The crude product isolated from step 1 (18.5 g, 38.7 mmol) was dissolved in cyclohexane (150 mL), 4-fluoro-3-methoxyaniline (5.46 g, 38.7 mmol) was added and the resulting mixture was refluxed (at about 110 °C) for 17 h while removing the formed water. After 17 h reaction time, the reaction mixture was concentrated under reduced pressure to afford the desired product as a brown oil (22.9 g) which was directly engaged in the next step.
  • step 2 To the crude product isolated from step 2 (51.2 g, 72.9 mmol) was added phosphoryl trichloride (50 mL, 536 mmol) and the resulting mixture was heated at 100 °C to react for 2 h. The temperature of the reaction mixture was lowered to 5 °C, dichloromethane (50 mL) was added and water (500 mL) was slowly added under vigorous stirring while maintaining the temperature below 15 °C. The reaction mixture was extracted with dichloromethane (300 mL), the organic layer was collected, was washed sequentially with aqueous saturated sodium hydrogen carbonate (250 mL) and with water (250 mL) and was concentrated under reduced pressure.
  • phosphoryl trichloride 50 mL, 536 mmol
  • the obtained residue was triturated with ethanol (200 mL) at 45 °C for 20min.
  • the formed suspension was filtered, the wet cake was rinsed with ethanol (150 mL) and the obtained solid was dried under reduced pressure at 40 °C to afford the desired product as a white solid (29.3 g, 60.7 mmol).
  • the wet cake was sequentially rinsed with water (250 mL) and with acetone (2 x 125 mL) and the obtained solid was dried under reduced pressure at 40 °C to deliver the desired product as a white solid (23.1 g, 50 mmol).
  • Step 1 Preparation of methyl 3-((4-chloro-3-methoxyphenyl)amino)-2-(4-(4-
  • step 1 To the crude product isolated from step 1 (2.9 g) was added phosphoryl trichloride (10.6 mL, 114 mmol) and the resulting mixture was heated at 100 °C to react for 135 min. The temperature of the reaction mixture was lowered to 5 °C, dichloromethane (50 mL) was added and water (100 mL) was slowly added under vigorous stirring while maintaining the temperature below 15 °C. The reaction mixture was extracted with dichloromethane (25 mL), the organic layer was collected, was washed sequentially with aqueous saturated sodium hydrogen carbonate (50 mL) and with water (50 mL) and was concentrated under reduced pressure. The obtained residue was triturated with ethanol (10 mL) at 45 °C for 20min. The formed suspension was filtered, the wet cake was rinsed with ethanol (10 mL) and the obtained solid was dried under reduced pressure at 40 °C to afford the desired product as a white solid (1.3 g, 2.49 mmol).
  • Step 1 Preparation of l-(4-(4-(trifhioromethoxy)phenoxy) phenyl)ethan-l-one (Compound 3)
  • Step 2 Preparation of methyl 2-(4-(4-(trifluoromethoxy)phenoxy)phenyl)acetate (Compound 4)
  • step 1 The crude product obtained from step 1 (218 g, 707 mmol) was dissolved in methanol (1740 mL), trimethoxymethane (618 mL, 5652 mmol) was added and the temperature of the resulting mixture was adjusted to 5 °C. Concentrated sulfuric acid (315 mL, 5652 mmol) and phenyliodine(III) diacetate (244 g, 742 mmol) were sequentially added under stirring while holding the temperature of the reaction mixture between 6 to 15 °C. After completion of the additions, the reaction mixture was allowed to reach room temperature and was stirred for 75 min. The temperature was then adjusted to 9 °C and cold water (3.5 L) was added.
  • the resulting mixture was extracted with methyl /c/V-buthylether (2 L) and the organic layer was sequentially washed with aqueous saturated sodium hydrogencarbonate (I L) and aqueous saturated sodium chloride (1 L).
  • the organic layer was first concentrated at 45 °C and then the pressure was gradually reduced to 3 mbar while the temperature was increased to 60 °C.
  • About 95 g iodobenzene was distilled off to afford the desired product (272 g, 80 wt.%) in the presence of iodobenzene (8 wt.%).
  • Step 3 Preparation of methyl 3-oxo-2-(4-(4-(trifluoromethoxy)phenoxy)phenyl) butanoate (Compound 5)
  • the temperature of the resulting solution was set to - 36 °C and a IM solution of lithium bis(trimethylsilyl)amide in tetrahydrofuran (1609 mL, 1609 mmol) was added while maintaining the temperature between -36 to -28 °C. After completion of the addition, the resulting mixture was stirred for 1 h between -30 to -28 °C. Cooling was stopped and aqueous saturated ammonium chloride (1.5 L) was slowly added to the reaction mixture which resulted in an increase in temperature to -1 °C. The mixture was allowed to reach room temperature and was stirred for 1 h. After dilution with water (1 L), the mixture was extracted with cyclohexane (550 mL). The organic layer was sequentially washed with aqueous IN hydrochloric acid (1 L), with brine (2 L) and was concentrated under reduced pressure to a volume of -650 mL which was directly engaged in the next step.
  • Step 4 Preparation of methyl 3-((4-fluoro-3-methoxyphenyl)amino)-2-(4-(4-
  • the concentrated product solution in cyclohexane (-650 mL) from step 3 (225 g, 610 mmol) was diluted with cyclohexane (1 L), 4-fluoro-3 -methoxyaniline (90 g, 610 mmol) was added and the resulting mixture was refluxed (at about 100 °C) for 20 h while removing the formed water. After 20 h reaction time, the reaction mixture was cooled down to 50°C, filtered over celite 545 and concentrated under reduced pressure to a volume of -400 mL which was directly engaged in the next step.
  • the temperature of the reaction mixture was lowered to ambient temperature, dichloromethane (800 mL) was added and the resulting mixture was slowly added to ice cold water (2 L) under vigorous stirring, while maintaining the temperature between 5°C and 15 °C.
  • the phases were allowed to settle and the aqueous layer was extracted with di chloromethane (500 mL).
  • the combined organic layers were washed sequentially with aqueous saturated sodium hydrogen carbonate (1.5 L) and with water (1.5 L) and concentrated under reduced pressure.
  • the obtained residue was triturated with ethanol (500 mL) at 45 °C for 20 min.
  • the formed suspension was filtered, the wet cake was rinsed with ethanol (150 mL) and the obtained solid was dried under reduced pressure at 40 °C to afford the desired product as a white solid (177.5 g, 371 mmol).
  • Steps 1 to 3 of example 6 were reproduced and steps 4 and 5 of example 6 were performed using 3 -methoxyaniline instead of 4-fluoro-3-methoxyaniline to deliver the desired 4-chloro-7- methoxy-2-methyl-3-(4-(4-(trifluoromethoxy)phenoxy)phenyl) quinoline.
  • Step 6 Preparation of 7-methoxy-2-methyl-3-(4-(4 (trifluoromethoxy)phenoxy)phenyl) quinolin-4( 1 H)-one

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

A new scalable synthesis for the preparation of endochin-like quinolone compounds of Formula (I), wherein R is H, Cl or F, preferably F and R2 is C1-C2 alkyl, preferably C1 alkyl, wherein the synthesis comprises a process for preparing a compound of Formula (4) wherein R1 is C1-C2 alkyl, preferably C1 alkyl.

Description

PROCESSES FOR MAKING ENDOCHIN-LIKE QUINOLONES FROM ALKYL 3-(3-
ALKOXYPHENYL)AMINO)-2-(4-(4-ALKOXY)PHENOXY)PHENYL)BUT-2 -ENOATE
Background
U.S. Patent No. 8,598,354 discloses endochin-like quinolone compounds having antiparasitic or anti-infectious activity including 6-fluoro-7-methoxy-2-methyl-3-(4- (4- (trifluoromethoxy)phenoxy)phenyl)quinolin-4(lH)-one (ELQ-316) (See Figure 4, sheet 23).
ELQ-316
McConnell et al, (ACS Infect. Dis. 2018, 4 ,1574-1584) discloses additional endochin-like quinolone compounds including 7-methoxy-2-methyl-3-(4-(4 (trifluoromethoxy)phenoxy)phenyl) quinolin-4(lH)-one (see Table 1, compound 7 B).
ELQ-298
WO/2021/231335 discloses synthetic methods and novel intermediates in the preparation of 3- aryl endochin-like quinolone (ELQ) compounds including ELQ-316 that are amenable to industrial scaleup production.
Hammers, et al. describe the use of (diacetoxyiodo)benzene (also known as phenyliodine(III) diacetate, PhI(OAc)2) and trimethyl orthoformate (TMOF) in methanol in the oxidative 1,2-aryl migration of a ketone to the corresponding a-methyl ester (Org. Biomol. Chem. 2021, 19, 2213- 2223).
Attempts to perform the oxidative rearrangement of intermediate 3 into compound 4 either in the presence of iodic acid and sulfuric acid as described by Krishnacharya G. Akamanchi and coworkers in ARKIVOC 2011 (v) 67-75 or in the presence of iodine in trimethylorthoformate as described by Yamauchi et al. in J. Org. Chem.1988, 53, 4858-4859; failed to produce the desired product 4.
Pou, et al. disclose synthetic routes to endochin-like quinolone compounds such as ELQ-300, ELQ-316, and other antiparasitic quinolones (Org. Process Res. Dev. 2021, 25, 1841-1852). Specifically, Pou discloses another process for making a compound similar to compound 4 which involves the use of a metal (copper) at elevated temperature 160 °C. However, the reported yields remain moderate, 60% - 70%. Furthermore, Pou describes the use of acetic anhydride for introducing an acetyl group on compound 4 which leads to a mixture of compounds 5 and 5a. This mixture needs to be treated with an acid (para toluenesulfonic acid, TsOH) to convert 5a back to 5. This is an additional step and it is not easy to remove the TsOH from the product which had to be carried over in the next step.
Vaswani et al. (Org. Lett. 2014, 16, 4114-4117) discloses the use of lithium bis(trimethylsilyl)amide (LiHMDS) and l-(lH-imidazol-l-yl)ethanone at low temperature to acylate aryl a-methyl esters.
Atkins et al. (Org. Proc. Res. Dev. 1997, 1, 185-197) disclose ring closure reactions using POCh at low temperature.
WO2021231335 discloses novel intermediates useful in the synthesis of endochin-like quinolone compounds. Summary of the Invention
An embodiment of the invention is a process for preparing a compound of Formula 4 wherein Ri is C1-C2 alkyl, preferably Ci alkyl, comprising reacting a compound of Formula 3 with phenyliodonium diacetate (PhI(OAc)2) and an orthoformate to yield the compound of
Formula 4.
Detailed Descriptions A new scalable synthesis for the preparation of endochin-like quinolone compounds of Formula
(I)
Wherein R2 is C1-C2 alkyl, preferably Ci alkyl, wherein R is H, Cl or F, and Ri is C1-C2 alkyl which avoids the use of any metal catalysis (e.g. copper) and of harsh reaction conditions and allows the final compound to be isolated in very high purity (>99%) and in the absence of any trace of residual metal. Scheme 1 is representative where R is F and R2 is methyl.
Scheme 1
It has been discovered that the use of copper can be circumvented by reacting 4-fluoro acetophenone (Compound 1) with /?-trifluoromethoxyphenol (Compound 2) in the presence of a base at 100 to 140 °C. This temperature range is lower that other known similar reaction and is a significant advantage when the process is run at industrial scale. The resulting diarylether acetophenone (Compound 3) was obtained in nearly quantitative yield and then underwent an oxidative rearrangement to deliver the ester intermediate (Compound 4) in high yield and purity. This novel process allowed the isolation of compound (Compound 4) in the absence of any trace of residual metal. It is advantageous to avoid the use of copper in the synthesis of an active pharmaceutical ingredient (API). The process is applicable for large scale/industrial use.
It has also been discovered that the ester (Compound 4) can be conveniently converted into the keto-ester (Compound 5) in one step by using a base and acetylimidazole as alkylating agent and by carefully quenching the reaction mixture at low temperature (<10°C). This novel process allowed the isolation of the target keto-ester (Compound 5) in high yield and high purity. Under these new reaction conditions, the formation of the side product 5a, as reported in the literature, was not observed.
Further, it has been determined that a condensation / ring closing reaction performed in the presence of phosphorus oxychloride (POCh) under mild reaction conditions (80°C) allowed the isolation of a chloroquinoline intermediate (Compound 8) in high yield (-75%) and very high purity (>99%). This intermediate (Compound 8) was then converted into 6-fluoro-7-methoxy-2- methyl-3-(4- (4-(trifluoromethoxy)phenoxy)phenyl)quinolin-4(lH)-one in quantitative yield in the presence of sodium acetate in acetic acid. This compound was isolated in very high purity (>99%) and in the absence of any trace of residual metal.
AcOH is acetic acid.
AcONa is sodium acetate.
DMF is A,A-dimethyl formamide.
DMSO is dimethylsulfoxide.
LiHMDS is lithium bis(trimethylsilyl)amide or lithium hexamethyldisilazane.
LIMP is lithium tetramethylpiperidide.
LDA is lithium diisopropylamide.
MeOH is methanol.
NMP is A-methyl-2-pyrrolidone.
PCh is phosphorus trichloride.
PCh is phosphorous pentachloride.
PhI(OAc)2 is (diacetoxyiodo)benzene or phenyliodonium diacetate.
POCI3 is phosphorus oxychloride.
THF is tetrahydrofuran.
TMOF is trimethyl orthoformate.
Residual metals in pharmaceuticals that have no therapeutic value are considered contaminants and their levels are strictly controlled by the various regulatory agencies around the world (ICH guideline Q3D (R2) on elemental impurities). Substantially free means not present in numbers or quantities in excess of those that can be expected to result from and be consistent with normal handling and good cultural practices employed in the production and marketing of the commodity. With respect to residual metal, for example copper, in an active pharmaceutical ingredient (api) given parenterally, it means less than 300 ppm of the residual metal in the api composition.
An embodiment of the invention is a process for preparing a compound of Formula 4 wherein Ri is C1-C2 alkyl, preferably Ci alkyl, comprising reacting a compound of Formula 3 with phenyliodonium diacetate (PhI(OAc)2) and an orthoformate to yield the compound of Formula 4.
In another embodiment of the invention, the orthoformate is trimethyl- or triethyl- orthoformate, preferably trimethyl orthoformate (TMOF).
In another embodiment of the invention, the reaction is conducted in an alcohol.
In another embodiment of the invention, the alcohol is methanol, ethanol, n-propanol or isopropanol, preferably methanol.
In another embodiment of the invention, the compound of Formula 3 is produced by reacting a compound of Formula 1 with a compound of Formula 2 to yield the compound of Formula 3, wherein the temperature of the reaction is between about 100°C to about 170°C, between about 100°C to about 150°C, between about 125°C to about
150°C, between about 130°C to about 150°C, between about 100°C to about 145°C, between about 125°C to about 145°C, between about 100°C to about 140°C, preferably about 135°C to about 145°C.
In another embodiment the temperature is about 140°C. In another embodiment of the invention, the reaction further comprises a base.
In another embodiment of the invention, the base is potassium carbonate, sodium carbonate or cesium carbonate, preferably potassium carbonate.
In another embodiment of the invention, the base is sodium carbonate.
In another embodiment of the invention, the base is cesium carbonate. In another embodiment of the invention, the reaction further comprises a solvent.
In another embodiment of the invention, the solvent is /V,/V-di methyl formamide (DMF), N- methyl-2-pyrrolidone (NMP) or dimethylsulfoxide (DMSO), preferably DMF.
In another embodiment of the invention, the solvent is NMP.
In another embodiment of the invention, the solvent is DMSO. In an alternative embodiment of the invention, the process further comprises reacting the compound of Formula 4 to produce the compound of Formula (I) wherein R is H, Cl or F, preferably F and R2 is C1-C2 alkyl, preferably Ci alkyl. In another embodiment of the invention, R is Cl and R2 is Ci alkyl.
In another embodiment of the invention, R is F and R2 is Ci alkyl.
In another embodiment of the invention, R is H and R2 is Ci alkyl.
In another embodiment of the invention, the compound of Formula (I) is substantially free of residual metal. Another embodiment of the invention is a compound of Formula 4
An embodiment of the invention is a process for preparing a compound of Formula 5 wherein Ri is C1-C2 alkyl, preferably Ci alkyl, comprising reacting a compound of Formula 4 with a base and then an alkylating agent to produce the compound of Formula 5.
In another embodiment of the invention, the base is lithium bis(trimethylsilyl)amide (LiHMDS), lithium tetramethylpiperidide (LTMP) or lithium diisopropylamide (LDA), preferably LiHMDS. In another embodiment of the invention, the base is LTMP.
In another embodiment of the invention, the base is LDA.
In another embodiment of the invention, the alkylating agent is acetylimidazole.
In another embodiment of the invention, the process is quenched at a temperature less than about 0°C to about 20°C, preferably less than about 10°C. In another embodiment of the invention, the process is quenched at a temperature of between about 0°C to about 20°C, or between about 0°C to about 10°C or between about 10°C to about 20°C.
In an alternative embodiment of the invention, the process further comprises reacting the compound of Formula 5 to produce the compound of Formula (I) wherein R is H, Cl or F, preferably F and R2 is C1-C2 alkyl, preferably Ci alkyl.
In another embodiment of the invention, R is Cl and R2 is Ci alkyl.
In another embodiment of the invention, R is F and R2 is Ci alkyl.
In another embodiment of the invention, R is H and R2 is Ci alkyl. Another embodiment of the invention is a compound of Formula 5
An embodiment of the invention is a process for preparing a compound of Formula 7 wherein R is H, Cl or F, preferably F and Ri is C1-C2 alkyl, preferably Ci alkyl, comprising reacting a compound of Formula 5 with a compound of Formula 6 wherein R is H, Cl or F, preferably F and R2 is C1-C2 alkyl, preferably Ci alkyl. yield the compound of Formula 7.
In another embodiment of the invention, a solvent is used in the process. In another embodiment of the invention, the solvent is an aprotic apolar solvent such as cyclohexane, toluene, heptane, xylene, or mixtures thereof, preferably cyclohexane.
In another embodiment of the invention, the solvent is heptane.
In another embodiment of the invention, the solvent is toluene. In another embodiment of the invention, the temperature of the process is between about 50 °C and about 140 °C, between about 60 °C and about 130 °C, about 70 °C and about 120 °C, about 80 °C and about 120 °C, about 85 °C and about 110 °C, preferably about 90 °C and about 110 °C.
In another embodiment the temperature is about 110°C.
In an alternative embodiment of the invention, the process further comprises reacting the compound of Formula 7 with phosphorus oxychloride (POCh), phosphorus trichloride (PCI3), or phosphorous pentachloride (PCI5), preferably POCI3, to yield a compound of Formula 8 wherein R is H, Cl or F, preferably F and R2 is C1-C2 alkyl, preferably Ci alkyl.
In another embodiment of the invention, the temperature of the process is between about 50 °C and about 140 °C, between about 60 °C and about 130 °C, about 70 °C and about 120 °C, about 80 °C and about 120 °C, about 85 °C and about 110 °C, preferably about 90 °C and about 110 °C.
In another embodiment the temperature is about 100°C.
In an alternative embodiment of the invention, the process further comprises reacting the compound of Formula 8 to produce the compound of Formula (I) wherein R is H, Cl or F, preferably F and R2 is C1-C2 alkyl, preferably Ci alkyl.
In another embodiment of the invention, R is Cl and R2 is Ci alkyl.
In another embodiment of the invention, R is F and R2 is Ci alkyl. In another embodiment of the invention, R is H and R2 is Ci alkyl.
In another embodiment, the process to form the compound of Formula (I) from the compound of Formula 8 is carried out in situ from the process to form the compound of Formula 8 from the compound of Formula 7. Another embodiment of the invention is a compound of Formula 7
An embodiment of the invention is a process for preparing a compound of Formula (I) comprising reacting a compound of Formula 8 with an acetate salt in an acid to yield the compound of Formula (I), wherein R is H, Cl or F, preferably F and R2 is C1-C2 alkyl, preferably Ci alkyl.
In another embodiment of the invention, R is Cl and R2 is Ci alkyl. In another embodiment of the invention, R is F and R2 is Ci alkyl.
In another embodiment of the invention, R is H and R2 is Ci alkyl.
In another embodiment of the invention, the acetate salt is potassium acetate or sodium acetate, preferably sodium acetate.
In another embodiment of the invention, the acetate salt is potassium acetate. In another embodiment of the invention, the acid is acetic acid or a C1-C4 aliphatic acid, preferably acetic acid.
In another embodiment of the invention, the acid is a C1-C4 aliphatic acid.
In another embodiment of the invention, the process to form the compound of Formula (I) from the compound of Formula 8 is carried out in situ from a process to form the compound of Formula 8 from the compound of Formula 7
An alternative embodiment of the invention is a to produce the compound of Formula (I) wherein R is H, Cl or F, preferably F and R2 is C1-C2 alkyl, preferably Ci alkyl, comprising i) reacting a compound of Formula 1 with a compound of Formula 2 to yield the compound of Formula 3, wherein the temperature of the reaction is between about 100°C to about 170°C; ii) reacting a compound of Formula 3 with phenyliodonium diacetate (PhI(OAc)2) and an orthoformate to produce the compound of Formula 4 iii) reacting a compound of Formula 4 with a base and then an alkylating agent to produce the compound of Formula 5 iv) reacting the compound of Formula 5 with a compound of formula 6 to produce the compound of Formula (I).
An alternative embodiment of the invention is a to produce the compound of Formula (I) wherein R is H, Cl or F, preferably F and R2 is C1-C2 alkyl, preferably Ci alkyl, comprising i) reacting a compound of Formula 1 with a compound of Formula 2 to yield the compound of Formula 3, wherein the temperature of the reaction is between about 100°C to about 170°C; ii) reacting a compound of Formula 3 with phenyliodonium diacetate (PhI(OAc)2) and an orthoformate to produce the compound of Formula 4 iii) reacting a compound of Formula 4 with a base and then an alkylating agent to produce the compound of Formula 5 iv) reacting the compound of Formula 5 with a compound of Formula 6 wherein R is H, Cl or F, preferably F and R2 is C1-C2 alkyl, preferably Ci alkyl. yield the compound of Formula 7 wherein R is H, Cl or F, preferably F and Ri is C1-C2 alkyl, preferably Ci alkyl,; v) reacting the compound of Formula 7 to produce a compound of Formula 8 vi) reacting the compound of Formula 8 to produce the compound of Formula (I). An alternative embodiment of the invention is a to produce the compound of Formula (I) wherein R is H, Cl or F, preferably F and R2 is C1-C2 alkyl, preferably Ci alkyl, comprising i) reacting a compound of Formula 1 with a compound of Formula 2 to yield the compound of Formula 3, wherein the temperature of the reaction is between about 100°C to about 170°C; ii) reacting a compound of Formula 3 with phenyliodonium diacetate (PhI(OAc)2) and an orthoformate to produce the compound of Formula 4 iii) reacting a compound of Formula 4 with a base and then an alkylating agent to produce the compound of Formula 5 iv) reacting the compound of Formula 5 with a compound of Formula 6 wherein R is H, Cl or F, preferably F and R2 is C1-C2 alkyl, preferably Ci alkyl. yield the compound of Formula 7 wherein R is H, Cl or F, preferably F and Ri is C1-C2 alkyl, preferably Ci alkyl,; v) reacting the compound of Formula 7 to produce a compound of Formula 8 vi) reacting the compound of Formula 8 with an acetate salt in an acid to produce the compound of Formula (I).
In an alternative embodiment, intermediate compounds 3, 4, 5 and 7 are carried on to the subsequent reaction step in concentrated solutions without complete drying.
In an alternative embodiment, the intermediate compound 3 is carried on to the subsequent reaction step in a concentrated solution without complete drying.
In an alternative embodiment, the intermediate compound 4 is carried on to the subsequent reaction step in a concentrated solution without complete drying.
In an alternative embodiment, the intermediate compound 5 is carried on to the subsequent reaction step in a concentrated solution without complete drying. In an alternative embodiment, the intermediate compound 7 is carried on to the subsequent reaction step in a concentrated solution without complete drying.
EXAMPLES
HPLC method:
Method A
Agilent Technologies UHPLC/MSD 6130 B Series 1290 composed of binary pump G7120A included degasser, Well plate sampler G4226A, Column oven G1316B, Diode array detector G4212A, Mass detector G6130B Quadrupole LC/MS with ESLsource.
Column: Waters XP, 2.1 x 50mm Xbndge BEH Cl 8 2.5 p, T = 40 °C;
Eluents: A: acetonitrile with 0.05 % (vol./vol.) formic acid.
B: water with 0.05 % formic acid (vol./vol.);
Flow: 0.8 mL/min;
Gradient: from 2 to 100 % eluent A 1.2 min, 0.5 min 100 % eluent A;
Run time: 2.2 min;
Detection: ESI/MS, positive and negative ions scan: 100-1000 m/z;
UV at 254 and 210 nm.
Example 1 : Preparation of methyl 2-(4-(4-(trifluoromethoxy)phenoxy)phenyl) acetate (Compound 4)
Step 1: Preparation of l-(4-(4-(trifhioromethoxy)phenoxy) phenyl)ethan-l-one (Compound 3)
Potassium carbonate (39.6 g, 287 mmol) was added to a solution of l-(4-fluorophenyl)ethan-l- one (17.70 mL, 143 mmol) and 4-(trifhioromethoxy)phenol (20.84 mL, 158 mmol) in N,N- dimethylformamide (400 mL). The resulting mixture was heated to 140 °C and was stirred at this temperature for 16 h. The reaction mixture was then allowed to reach room temperature, was diluted with water (1 L) and was extracted with ethyl acetate (2 x 500 mL). The combined organic layers were washed with aqueous IN hydrochloric acid (500 mL), were dried and concentrated under reduced pressure to afford a brown oil. The obtained oil was dissolved in di chloromethane (1 L), was filtered over a short pad of silica gel and the filtrate was concentrated under reduced pressure to afford the desired product as a brown oil (43.6 g, 140 mmol) which was directly engaged in step 2.
NMR
'H NMR (300 MHz, Methanol-d3) 8 (ppm): 8.04 - 8.01 (m, 2H); 7.35 (d, J = 8.4 Hz, 2H); 7.20 -
7.15 (m, 2H); 7.08 - 7.04 (m, 2H); 2.58 (s, 3H)
13C NMR (75 MHz, Methanol-d3) 8 (ppm): 197.7; 161.6; 154.4; 145.4; 132.2; 130.6; 122.8; 121.0; 117.2; 25.2
UPLC/MS (Method A): Rt = 1.23 mm.
Step 2: Preparation of methyl 2-(4-(4-(trifluoromethoxy)phenoxy)phenyl)acetate (Compound 4)
The crude product obtained from step 1 (43.6 g, 140 mmol) was dissolved in methanol (430 mL), trimethoxymethane (127 mL, 1161 mmol) was added and the temperature of the resulting mixture was adjusted to 10 °C. Concentrated sulfuric acid (64.8 mL, 1161 mL) and phenyliodine(III) diacetate (50.1 g, 152 mmol) were sequentially added while holding the temperature of the reaction mixture between 10 to 16 °C. After completion of the additions, the reaction mixture was allowed to reach room temperature and was stirred for 90 min. The temperature was then adjusted to 5 °C and water (500 mL) was added. The volume of the resulting mixture was reduced under reduced pressure (distillated volume ~ 70 mL), water (I L) was added and the pH was set to 7 by the addition of sodium hydrogen carbonate. The aqueous solution was extracted with dichloromethane (2 x 300 mL) and the combined organic layers were dried and concentrated under reduced pressure to afford the desired product (71.3 g, 63 wt.%) in the presence of iodobenzene (37 wt.%).
1 H NMR (600 MHz, Dichloromethane-d2) 8 (ppm): 7.33 - 7.28 (m, 2H); 7.24 (dd, J= Q.l, 9.0 Hz, 2H); 7.07 - 7.04 (m, 2H); 7.03 - 7.00 (m, 2H); 3.72 (s, 3H); 3.65 (s, 1H)
13C NMR (75 MHz, Methanol-d3) 8 (ppm): 171.9; 155.9; 144.4; 130.8; 129.8; 122.6; 121.4; 119.6; 118.9; 51.9; 40.1
UPLC/MS (Method A): Rt = 1.26 mm; m/z 325. Example 2: Preparation of 4-chloro-6-fluoro-7-methoxy-2-methyl-3-(4-(4- (trifluoromethoxy)phenoxy)phenyl)quinoline (Compound 8)
Step 1: Preparation of methyl 3-oxo-2-(4-(4-(trifluoromethoxy)phenoxy)phenyl) butanoate (Compound 5)
Methyl 2-(4-(4-(trifluoromethoxy)phenoxy)phenyl)acetate (20.0 g, 63 wt.%, 38.6 mmol) obtained from step 2 of example 1 and l-(177-imidazol-l-yl)ethan-l-one (5.1 g, 46.3 mmol) were placed under nitrogen atmosphere and were dissolved in a mixture of dry tetrahydrofuran (200 mL) and dry 7V,7V-di methylacetamide (20 mL). The temperature of the resulting solution was set to - 30 °C and a IM solution of lithium bis(trimethylsilyl)amide in tetrahydrofuran (93 mL, 93 mmol) was added while maintaining the temperature between -31 to -28 °C. After completion of the addition (about 20 min), the resulting mixture was stirred for 1 h between -30 to -25 °C. Cooling was stopped and saturated aqueous ammonium chloride (100 mL) was slowly added to the reaction mixture which resulted in an increase in temperature to -1 °C. The mixture was allowed to reach room temperature and was stirred for 30 min. After dilution with water (200 mL), the mixture was extracted with ethyl acetate (200 mL). The organic layer was sequentially washed with aqueous 2N hydrochloric acid (200 mL), with brine (200 mL) and was concentrated under reduced pressure to afford the desired product as a brown oil (18.5 g) which was directly engaged in the next step.
UPLC/MS (Method A): Rt = 1.16, 1.23, 1.26 and 1.36 mm; m/z 367.
Step 2: Preparation of methyl 3-((4-fluoro-3-methoxyphenyl)amino)-2-(4-(4-
(trifluoromethoxy)phenoxy)phenyl)but-2-enoate (Compound 7)
The crude product isolated from step 1 (18.5 g, 38.7 mmol) was dissolved in cyclohexane (150 mL), 4-fluoro-3-methoxyaniline (5.46 g, 38.7 mmol) was added and the resulting mixture was refluxed (at about 110 °C) for 17 h while removing the formed water. After 17 h reaction time, the reaction mixture was concentrated under reduced pressure to afford the desired product as a brown oil (22.9 g) which was directly engaged in the next step.
Step 3: Preparation of 4-chloro-6-fluoro-7-methoxy-2-methyl-3-(4-(4-
(trifluoromethoxy)phenoxy)phenyl)quinoline (Compound 8)
To the crude product isolated from step 2 (51.2 g, 72.9 mmol) was added phosphoryl trichloride (50 mL, 536 mmol) and the resulting mixture was heated at 100 °C to react for 2 h. The temperature of the reaction mixture was lowered to 5 °C, dichloromethane (50 mL) was added and water (500 mL) was slowly added under vigorous stirring while maintaining the temperature below 15 °C. The reaction mixture was extracted with dichloromethane (300 mL), the organic layer was collected, was washed sequentially with aqueous saturated sodium hydrogen carbonate (250 mL) and with water (250 mL) and was concentrated under reduced pressure. The obtained residue was triturated with ethanol (200 mL) at 45 °C for 20min. The formed suspension was filtered, the wet cake was rinsed with ethanol (150 mL) and the obtained solid was dried under reduced pressure at 40 °C to afford the desired product as a white solid (29.3 g, 60.7 mmol).
NMR
1 H NMR (300 MHz, Dimethysulfoxide-d6) 8 (ppm): 7.89 (d, J= 6.0 Hz, 1H); 7.66 (d, J= 4.2 Hz, 1H); 7.45 (d, J= 4.2 Hz, 2H); 7.41 - 7.39 (m, 2H); 7.24 - 7.23 (m, 2H); 7.20 - 7.18 (m, 2H);
4.04 (s, 3H); 2.40 (s, 3H) 13C NMR (75 MHz, Dimethysulfoxide-d6) 8 (ppm): 158.2; 156.7; 155.6; 153.3; 151.6; 151.1; 151.0; 145.7; 144.5; 139.5; 139.4; 132.1; 123.6; 121.4; 120.9; 119.8; 119.4; 119.2; 110.6; 109.1; 108.9; 57.0; 25.4
19F NMR (282 MHz, Dimethysulfoxide-ds) 8 (ppm): -57.1; -131.1
UPLC/MS (Method A): Rt = 1.45 mm; m/z 325.
Example 3: Preparation of 6-fluoro-7-methoxy-2-methyl-3-(4-(4-
(trifluoromethoxy)phenoxy)phenyl)quinolin-4(lH)-one (Compound ELQ-316)
4-chloro-6-fluoro-7-methoxy-2-methyl-3-(4-(4-(trifluoromethoxy)phenoxy)phenyl) quinoline (28 g, 58.0 mmol) was dissolved in acetic acid (300 mL), sodium acetate was added (9.52 g, 116 mmol) and the resulting mixture was reacted at 120 °C for 16 h. The obtained suspension was allowed to reach room temperature, was diluted with water (300 mL) and was filtered. The wet cake was sequentially rinsed with water (250 mL) and with acetone (2 x 125 mL) and the obtained solid was dried under reduced pressure at 40 °C to deliver the desired product as a white solid (23.1 g, 50 mmol).
NMR
' H NMR (300 MHz, A,A-Dimethylformamide-d7) 8 (ppm): 7.83 (d, J = 11.5 Hz, 1H); 7.49 (d, J = 8.8 Hz, 1H); 7.42 - 7.40 (m, 2H); 7.27 - 7.24 (m, 2H); 7.22 (d, J= 6.9 Hz, 1H); 7.15 - 7.13 (m, 2H); 4.05 (s, 3H); 2.36 (s, 3H)
13C NMR (75 MHz, A,A-Dimethylformamide-d7) 8 (ppm): 174.4; 156.5; 155.3; 151.5; 151.4; 150.3; 148.7; 146.5; 144.2; 137.6; 132.3; 123.2; 121.5; 119.9; 118.5; 110.4; 110.3; 56.1; 18.6 19F NMR (282 MHz, A,A-Dimethylformamide-d7) 8 (ppm): -57.2; -140.7 UPLC/MS (Method A): Rt = 1.13 mm; m/z 460.
Example 4: Preparation of 4,6-dichloro-7-methoxy-2-methyl-3-(4-(4- (trifluoromethoxy)phenoxy)phenyl)quinoline
Step 1: Preparation of methyl 3-((4-chloro-3-methoxyphenyl)amino)-2-(4-(4-
(trifluoromethoxy)phenoxy)phenyl)but-2-enoate
The crude product isolated from step 1 of example 2 (2.0 g, 5.43 mmol) was dissolved in cyclohexane (15 mL), 4-chloro-3-methoxyaniline (0.87 g, 5.43 mmol) was added and the resulting mixture was refluxed (at about 110 °C) for 24 h while removing the formed water. Heating was stopped and the reaction mixture was concentrated under reduced pressure to afford the desired product as a brown oil (2.9 g) which was directly engaged in the next step.
Step 2: Preparation of 4,6-dichloro-7-methoxy-2-methyl-3-(4-(4- (trifluoromethoxy)phenoxy)phenyl)quinoline
To the crude product isolated from step 1 (2.9 g) was added phosphoryl trichloride (10.6 mL, 114 mmol) and the resulting mixture was heated at 100 °C to react for 135 min. The temperature of the reaction mixture was lowered to 5 °C, dichloromethane (50 mL) was added and water (100 mL) was slowly added under vigorous stirring while maintaining the temperature below 15 °C. The reaction mixture was extracted with dichloromethane (25 mL), the organic layer was collected, was washed sequentially with aqueous saturated sodium hydrogen carbonate (50 mL) and with water (50 mL) and was concentrated under reduced pressure. The obtained residue was triturated with ethanol (10 mL) at 45 °C for 20min. The formed suspension was filtered, the wet cake was rinsed with ethanol (10 mL) and the obtained solid was dried under reduced pressure at 40 °C to afford the desired product as a white solid (1.3 g, 2.49 mmol).
NMR
' H NMR (300 MHz, Dimethysulfoxide-d6) 8 (ppm): 8.18 (s, 1H); 7.63 (s, 1H); 7.47- 7.45 (m, 2H); 7.42 - 7.40 (m, 2H); 7.24 - 7.23 (m, 2H); 7.20 - 7.19 (m, 2H); 4.05 (s, 3H); 2.41 (s, 3H)
13C NMR (75 MHz, Dimethysulfoxide-d6) 8 (ppm): 159.4; 156.7; 156.4; 155.6; 147.7; 144.5; 139.1; 132.5; 132.1; 131.8; 124.9; 124.6; 123.6; 121.4; 119.8; 119.2; 109.4; 57.3; 25.6
19F NMR (282 MHz, Dimethysulfoxide-de) 8 (ppm): -57.1
UPLC/MS (Method A): Rt = 1.50 mm; m/z 494.
Example 5: Preparation of 6-chloro-7-methoxy-2-methyl-3-(4-(4-
(trifluoromethoxy)phenoxy)phenyl)quinolin-4(lH)-one
4,6-Dichloro-7-methoxy-2-methyl-3-(4-(4-(trifluoromethoxy)phenoxy)phenyl) quinoline (1 g, 2.02 mmol) was dissolved in acetic acid (10 mL), sodium acetate (0.33 g, 4.05 mmol) was added and the resulting mixture was reacted at 120 °C for 17 h. The obtained suspension was allowed to reach room temperature, was diluted with water (15 mL) and was filtered. The wet cake was rinsed with water (10 mL) and the obtained solid was dried under reduced pressure at 40 °C to deliver the desired product as a white solid (0.9 g, 1.74 mmol).
UPLC/MS (Method A): Rt = 1.17 mm; m/z 476.
Example 6: Alternative preparation of 6-fluoro-7-methoxy-2-methyl-3-(4-(4- (trifluoromethoxy)phenoxy)phenyl)quinolin-4(lH)-one (Compound ELQ-316)
Step 1: Preparation of l-(4-(4-(trifhioromethoxy)phenoxy) phenyl)ethan-l-one (Compound 3)
Potassium carbonate (198 g, 1.433 mol) was added to a solution of l-(4-fluorophenyl)ethan-l- one (88 mL, 717 mmol) and 4-(trifhioromethoxy)phenol (99 mL, 752 mmol) in N,N- dimethylformamide (1000 mL). The resulting mixture was heated to 137 °C and was stirred at this temperature for 20 h. The reaction mixture was then allowed to reach room temperature, was diluted with water (2.5 L) and was extracted with methyl /c/7-buthylether (1 L). The organic layer was washed with aqueous IN hydrochloric acid (500 mL) and aqueous sat. sodium chloride (500 mL), was dried and concentrated under reduced pressure to afford the desired product as a brown oil (218 g, 707 mmol) which was directly engaged in step 2.
Step 2: Preparation of methyl 2-(4-(4-(trifluoromethoxy)phenoxy)phenyl)acetate (Compound 4)
The crude product obtained from step 1 (218 g, 707 mmol) was dissolved in methanol (1740 mL), trimethoxymethane (618 mL, 5652 mmol) was added and the temperature of the resulting mixture was adjusted to 5 °C. Concentrated sulfuric acid (315 mL, 5652 mmol) and phenyliodine(III) diacetate (244 g, 742 mmol) were sequentially added under stirring while holding the temperature of the reaction mixture between 6 to 15 °C. After completion of the additions, the reaction mixture was allowed to reach room temperature and was stirred for 75 min. The temperature was then adjusted to 9 °C and cold water (3.5 L) was added. The resulting mixture was extracted with methyl /c/V-buthylether (2 L) and the organic layer was sequentially washed with aqueous saturated sodium hydrogencarbonate (I L) and aqueous saturated sodium chloride (1 L). The organic layer was first concentrated at 45 °C and then the pressure was gradually reduced to 3 mbar while the temperature was increased to 60 °C. About 95 g iodobenzene was distilled off to afford the desired product (272 g, 80 wt.%) in the presence of iodobenzene (8 wt.%).
Step 3: Preparation of methyl 3-oxo-2-(4-(4-(trifluoromethoxy)phenoxy)phenyl) butanoate (Compound 5)
Methyl 2-(4-(4-(trifluoromethoxy)phenoxy)phenyl)acetate (272 g, 80 wt.%, 706 mmol) obtained from step 2 and l-(177-imidazol-l-yl)ethan-l-one (90 g, 804 mmol) were placed under nitrogen atmosphere and were dissolved in a mixture of dry tetrahydrofuran (2.4 L) and dry N,N- dimethylacetamide (440 mL). The temperature of the resulting solution was set to - 36 °C and a IM solution of lithium bis(trimethylsilyl)amide in tetrahydrofuran (1609 mL, 1609 mmol) was added while maintaining the temperature between -36 to -28 °C. After completion of the addition, the resulting mixture was stirred for 1 h between -30 to -28 °C. Cooling was stopped and aqueous saturated ammonium chloride (1.5 L) was slowly added to the reaction mixture which resulted in an increase in temperature to -1 °C. The mixture was allowed to reach room temperature and was stirred for 1 h. After dilution with water (1 L), the mixture was extracted with cyclohexane (550 mL). The organic layer was sequentially washed with aqueous IN hydrochloric acid (1 L), with brine (2 L) and was concentrated under reduced pressure to a volume of -650 mL which was directly engaged in the next step.
Step 4: Preparation of methyl 3-((4-fluoro-3-methoxyphenyl)amino)-2-(4-(4-
(trifluoromethoxy)phenoxy)phenyl)but-2-enoate (Compound 7)
The concentrated product solution in cyclohexane (-650 mL) from step 3 (225 g, 610 mmol) was diluted with cyclohexane (1 L), 4-fluoro-3 -methoxyaniline (90 g, 610 mmol) was added and the resulting mixture was refluxed (at about 100 °C) for 20 h while removing the formed water. After 20 h reaction time, the reaction mixture was cooled down to 50°C, filtered over celite 545 and concentrated under reduced pressure to a volume of -400 mL which was directly engaged in the next step.
Step 5: Preparation of 4-chloro-6-fluoro-7-methoxy-2-methyl-3-(4-(4-
(trifluoromethoxy)phenoxy)phenyl)quinoline (Compound 8)
To the concentrated solution of methyl 3-((4-fluoro-3-methoxyphenyl)amino)-2-(4-(4- (trifluoromethoxy)phenoxy)phenyl)but-2-enoate in cyclohexane (-400 mL) obtained from step 4 (264 g, 537 mmol) was added phosphoryl trichloride (253 mL, 2685 mmol) and the resulting mixture was heated at 100 °C until all cyclohexane distilled off (ca. 35 min), and was then stirred for another 2 h at 100°C. The temperature of the reaction mixture was lowered to ambient temperature, dichloromethane (800 mL) was added and the resulting mixture was slowly added to ice cold water (2 L) under vigorous stirring, while maintaining the temperature between 5°C and 15 °C. The phases were allowed to settle and the aqueous layer was extracted with di chloromethane (500 mL). The combined organic layers were washed sequentially with aqueous saturated sodium hydrogen carbonate (1.5 L) and with water (1.5 L) and concentrated under reduced pressure. The obtained residue was triturated with ethanol (500 mL) at 45 °C for 20 min. The formed suspension was filtered, the wet cake was rinsed with ethanol (150 mL) and the obtained solid was dried under reduced pressure at 40 °C to afford the desired product as a white solid (177.5 g, 371 mmol).
Step 6: Preparation of 6-fluoro-7-methoxy-2-methyl-3-(4-(4-
(trifluoromethoxy)phenoxy)phenyl)quinolin-4(lH)-one (Compound ELQ-316) 4-Chloro-6-fluoro-7-methoxy-2-methyl-3-(4-(4-(trifluoromethoxy)phenoxy)phenyl) quinoline (177.5 g, 371 mmol) was dissolved in acetic acid (1775 mL), sodium acetate was added (60.9 g, 743 mmol) and the resulting mixture was reacted at 120 °C for 16 h. The obtained suspension was allowed to reach room temperature, was diluted with water (1775 mL) and was filtered. The wet cake was sequentially rinsed with water (I L) and with acetone (2 x 500 mL) and the obtained solid was dried under reduced pressure at 40 °C to deliver the desired product as a white solid (150 g, 326 mmol).
Example 7: Preparation of 7-methoxy-2-methyl-3-(4-(4 (trifluoromethoxy)phenoxy)phenyl)- quinolin-4( 1 H)-one
Steps 1 to 3 of example 6 were reproduced and steps 4 and 5 of example 6 were performed using 3 -methoxyaniline instead of 4-fluoro-3-methoxyaniline to deliver the desired 4-chloro-7- methoxy-2-methyl-3-(4-(4-(trifluoromethoxy)phenoxy)phenyl) quinoline.
Step 6: Preparation of 7-methoxy-2-methyl-3-(4-(4 (trifluoromethoxy)phenoxy)phenyl) quinolin-4( 1 H)-one
4-Chloro-7-methoxy-2-methyl-3-(4-(4-(trifluoromethoxy)phenoxy)phenyl) quinoline (3.7 g, 7.72 mmol) was dissolved in acetic acid (37 mL), sodium acetate was added (1.27 g, 15.5 mmol) and the resulting mixture was reacted at 120 °C for 17 h. The reaction mixture was cooled to 65 °C, taken up in water (200 mL) and stirred for 15 min. The obtained suspension was filtered and rinsed with water (50 mL). The wet filter cake was taken up in acetone (80 mL) and stirred for 20 min at ambient temperature. The suspension was filtered and washed with acetone (20 mL). The filter cake was dried under reduced pressure at 40 °C to deliver the desired product as a white solid (2.9 g, 6.50 mmol).
1H NMR (600 MHz, Dimethysulfoxide-d6) 8 (ppm): 11.49 (s, 1H), 7.98 (d, J= 8.8 Hz, 1H), 7.41 (d, J= 8.8 Hz, 2H), 7.27 (d, J= 8.5 Hz, 2H), 7.16 (d, J= 9.1 Hz, 2H), 7.06 (d, J= 8.6 Hz, 2H), 6.94 - 6.86 (m, 2H), 3.86 (s, 3H), 2.22 (s, 3H). 13C NMR (151 MHz, Dimethysulfoxide-ds) 8 (ppm): 174.6, 161.6, 155.9, 154.6, 146.2, 143.6, 141.0, 131.9, 127.3, 123.4, 121.0, 119.8, 119.7, 119.3, 118.7, 118.4, 112.8, 98.5, 55.4, 18.9.
19F NMR (565 MHz, Dimethysulfoxide-de) 8 (ppm): -57.2.
UPLC/MS (Method A): Rt = 1.12 min, m/z 442.

Claims

1. A process for preparing a compound of Formula 4 wherein Ri is C1-C2 alkyl, preferably Ci alkyl, comprising reacting a compound of Formula 3 with phenyliodonium diacetate (PhI(OAc)2) and an orthoformate to yield the compound of Formula 4.
2. The process of claim 1 , wherein the orthoformate is trimethyl- or tri ethyl- orthoformate, preferably trimethyl orthoformate (TMOF).
3. The process of any one of claims 1-2, wherein the reaction is conducted in an alcohol.
4. The process of any one of claims 1-3, wherein the alcohol is methanol, ethanol, n-propanol or isopropanol, preferably methanol.
5. The process of any one of claims 1-4, wherein the compound of Formula 3 is produced by reacting a compound of Formula 1 with a compound of Formula 2 to yield the compound of Formula 3, wherein the temperature of the reaction is between about 100°C to about 150°C, preferably about 135°C to about 145°C.
6. The process of claim 4, wherein the reaction further comprises a base.
7. The process of claim 6, wherein the base is potassium carbonate, sodium carbonate or cesium carbonate, preferably potassium carbonate.
8. The process of any one of claims 5-7, wherein the reaction further comprises a solvent.
9. The process of claim 8, wherein the solvent is dimethyl formamide (DMF), /V-methyl-2- pyrrolidone (NMP) or dimethylsulfoxide (DMSO), preferably DMF.
10. The process of claim 1, further comprising reacting the compound of Formula 4 to produce the compound of Formula (I) wherein R is H, Cl or F, preferably F and R2 is C1-C2 alkyl, preferably Ci alkyl,
11. The process of any one of claims 1-10, wherein the compound of Formula (I) is substantially free of residual metal.
12. A compound of Formula 4
EP23817776.0A 2022-12-07 2023-12-06 Processes for making endochin-like quinolones from alkyl 3-(3- alkoxyphenyl)amino)-2-(4-(4-alkoxy)phenoxy)phenyl)but-2-enoate Pending EP4630395A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22212017.2A EP4382506A1 (en) 2022-12-07 2022-12-07 Processes for making endochin-like quinolones from phenoxy phenyl acetates
PCT/EP2023/084450 WO2024121199A1 (en) 2022-12-07 2023-12-06 Processes for making endochin-like quinolones from alkyl 3-(3- alkoxyphenyl)amino)-2-(4-(4-alkoxy)phenoxy)phenyl)but-2-enoate

Publications (1)

Publication Number Publication Date
EP4630395A1 true EP4630395A1 (en) 2025-10-15

Family

ID=84439810

Family Applications (2)

Application Number Title Priority Date Filing Date
EP22212017.2A Withdrawn EP4382506A1 (en) 2022-12-07 2022-12-07 Processes for making endochin-like quinolones from phenoxy phenyl acetates
EP23817776.0A Pending EP4630395A1 (en) 2022-12-07 2023-12-06 Processes for making endochin-like quinolones from alkyl 3-(3- alkoxyphenyl)amino)-2-(4-(4-alkoxy)phenoxy)phenyl)but-2-enoate

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP22212017.2A Withdrawn EP4382506A1 (en) 2022-12-07 2022-12-07 Processes for making endochin-like quinolones from phenoxy phenyl acetates

Country Status (5)

Country Link
EP (2) EP4382506A1 (en)
JP (1) JP2025538726A (en)
CN (1) CN120303240A (en)
MX (1) MX2025006552A (en)
WO (1) WO2024121199A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6567755B1 (en) * 2018-12-27 2019-08-28 株式会社マツモト交商 Oil-in-water sunscreen cosmetics

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8598354B2 (en) 2008-12-05 2013-12-03 University Of South Florida Compounds having antiparasitic or anti-infectious activity
EP4149510A4 (en) 2020-05-11 2024-05-22 Oregon Health & Science University Novel intermediates and synthesis for endochin-like quinolone compounds
US20240182421A1 (en) * 2021-03-19 2024-06-06 Oregon Health & Science University Synthesis of endochin-like quinolones

Also Published As

Publication number Publication date
MX2025006552A (en) 2025-07-01
EP4382506A1 (en) 2024-06-12
CN120303240A (en) 2025-07-11
WO2024121199A1 (en) 2024-06-13
JP2025538726A (en) 2025-11-28

Similar Documents

Publication Publication Date Title
CA2176788C (en) Process for producing 4-trifluoromethylnicotinic acid
EP0916675B1 (en) Process for preparing sildenafil
CA2656265A1 (en) Synthesis of diethyl{ i5&#34; (3 -fluorophenyl) -pyridine-2-yl] methyl} phosphonate used in the synthesis of himbacine analogs
EP4630395A1 (en) Processes for making endochin-like quinolones from alkyl 3-(3- alkoxyphenyl)amino)-2-(4-(4-alkoxy)phenoxy)phenyl)but-2-enoate
HU204258B (en) Process for producing intermediates for producing quinoline derivatives of antibacterial activity
CA1333715C (en) Process for the preparation of quinolonecarboxylic acids
WO2024121202A1 (en) Processes for making endochin-like quinolones from alkyl 3-(3-alkoxyphenyl)amino)-2-(4-(4-alkoxy)phenoxy)phenyl)but-2-enoate
WO2024121200A1 (en) Processes for making endochin-like quinolones from alkyl 3-(3-alkoxyphenyl)amino)-2-(4-(4-alkoxy)phenoxy)phenyl)but-2-enoate
WO2024121201A1 (en) Processes for making endochin-like quinolones from alkyl 3-(3-alkoxyphenyl)amino)-2-(4-(4-alkoxy)phenoxy)phenyl)but-2-enoate
US6187926B1 (en) Process for producing quinolone derivatives
US6699992B2 (en) Process for preparing quinolonecarboxylic acids
KR20180116371A (en) Process for producing 4-alkoxy-3-hydroxypicolic acid
KR101457453B1 (en) Process for preparing gefitinib and an intermediate used for preparing thereof
CN1849299A (en) Method for synthesizing 6-amino-4-[(3-chloro-4-fluorophenyl)amino]-7-ethoxy-quinoline-3-carbonitrile
KR100455471B1 (en) Process for the preparation of 2-substituted 5-chloroimidazole-4-carbaldehydes
TWI501973B (en) Method for producing n-substituted-2-amino-4-(hydroxymethylphosphinyl)-2- butenoic acid
AU705093B2 (en) Method for producing 3,4-dihydroxy-3-cyclobutene-1,2-dione
US4885386A (en) Process for the synthesis of 3-chloro-2,4,5-trifluorobenzoic acid
DK160503B (en) Anhydrides of 6-fluoro-7-chloro-1-methylamino-4-oxo-1,4- dihydroquinoline-3-carboxylic acid and boric acids
EP2880041B1 (en) Process for preparation of aryl phosphorous compounds
US6933388B2 (en) Process for the synthesis of 3-cyano-6-alkoxy-7-nitro-4-quinolones
IL175649A (en) Process for preparing 3-fluorinated quinolines and novel intermediates in the process
JP2593292B2 (en) Intermediate for synthesis of 6,7-dihydro-5,8-dimethyl-9-fluoro-1-oxo-1H, 5H-benzo [i, j] quinolidine-2-carboxylic acid and method for producing the same
AU2013389353B2 (en) Method for producing (1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinoline-carboxylic acid
JP4690733B2 (en) Method for producing 3-hydroxypyrazole-1-carboxamide derivative

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20250707

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)